Christopher Bowden - 18 Jun 2021 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role
Chief Medical Officer
Signature
/s/ William Cook, as Attorney-in-fact for Christopher Bowden
Issuer symbol
AGIO
Transactions as of
18 Jun 2021
Net transactions value
-$490,860
Form type
4
Filing time
22 Jun 2021, 16:44:19 UTC
Previous filing
21 Jun 2021
Next filing
24 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGIO Common stock Options Exercise $74,948 +1,885 +12% $39.76 17,372 18 Jun 2021 Direct F1
transaction AGIO Common stock Options Exercise $2,349,043 +46,608 +268% $50.40 63,980 18 Jun 2021 Direct F1
transaction AGIO Common stock Sale $2,914,851 -48,493 -76% $60.11 15,487 18 Jun 2021 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGIO Stock option (right to buy) Options Exercise $0 -1,885 -100% $0.000000* 0 18 Jun 2021 Common stock 1,885 $39.76 Direct F1, F4
transaction AGIO Stock option (right to buy) Options Exercise $0 -46,608 -98% $0.000000 992 18 Jun 2021 Common stock 46,608 $50.40 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3 The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.00 to $60.31. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4 This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F5 This option was granted on February 21, 2017. The shares underlying this option vest as to 25% of the underlying shares on February 21, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.